The "Tricky Business" of Identifying Mechanisms of Resistance to Anti-PD-1.
Resistance to immune checkpoint inhibitors can vary between patients and among metastases. Understanding the genomic, transcriptomic, and microenvironmental factors that contribute to this variability will reveal the mechanisms that tumors utilize to evade the therapeutic effects of checkpoint inhibitor immunotherapies and will enable us to develop strategies to overcome them. Clin Cancer Res; 23(12); 2921-3. ©2017 AACRSee related article by Ascierto et al., p. 3168.